PatenSee

Company Overview

Snapshot

Founded in March 2019 by Gal Goshen, Oz Seadia, and Hagay Drori, PatenSee operates with 11–50 employees. The company has raised $2.35M across two funding rounds from four investors. In September 2025, PatenSee received FDA Breakthrough Device Designation for its non-contact vascular access management system.

Business overview

PatenSee is a clinical-stage medical device company specializing in a contactless surveillance system for the early detection of asymptomatic vascular stenosis in hemodialysis patients. The company leverages advanced multimodal imaging technologies and machine learning to identify stenosis risk at its earliest stages, aiming to facilitate timely interventions and improve patient care. PatenSee operates within the Health Tech & Life Sciences sector, focusing on medical devices, digital healthcare, and diagnostics devices, serving the healthcare provider market.

Strategic signal

In September 2025, PatenSee secured FDA Breakthrough Device Designation for its non-contact vascular access management system. This designation signals significant regulatory validation and recognition of the technology's potential to address an unmet medical need, accelerating its path to market and indicating strong commercial prospects for investors.

Company Intelligence Q&A

What is PatenSee's core technology?

PatenSee develops a contactless surveillance system that utilizes advanced multimodal imaging technologies and machine learning to detect early asymptomatic vascular stenosis in hemodialysis patients.

When did PatenSee receive FDA Breakthrough Device Designation?

In September 2025, PatenSee announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for its non-contact vascular access management system for patients undergoing hemodialysis.

What was the outcome of PatenSee's clinical trial at Rabin Medical Center?

In March 2022, PatenSee announced successful clinical trial results at Rabin Medical Center, demonstrating the promise of its contactless imaging device in timely and accurately monitoring dialysis patients.

Which organizations participated in PatenSee's initial funding round?

In March 2019, PatenSee received funding from investors including Israel Innovation Authority.

When did PatenSee initiate its first in-human trial?

In February 2021, PatenSee initiated its first in-human trial with its contactless imaging surveillance system for patients undergoing hemodialysis.